Abstract #2728

Association between cardiac iron clereance and hepatic siderosis by T2* MRI in thalassemia major patients

Antonella Meloni¹, Laura Pistoia¹, Nicolò Schicchi², Gennaro Restaino³, Paolo Preziosi⁴, Vincenzo Positano¹, Monica Benni⁵, Maria Paola Smacchia⁶, Daniele De Marchi¹, and Alessia Pepe¹

¹CMR Unit, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy, ²Azienda Ospedaliero-Universitaria Ospedali Riuniti "Umberto I-Lancisi-Salesi", Ancona, Italy, ³Fondazione di Ricerca e Cura "Giovanni Paolo II", Campobasso, Italy, ⁴Ospedale Sandro Pertini, Roma, Italy, ⁵Policlinico S. Orsola "L. e A. Seragnoli", Bologna, Italy, ⁶Policlinico Umberto 1, Roma, Italy

We evaluated in thalassemia major (TM) if the cardiac efficacy of the three iron chelators (Desferrioxamine, Deferiprone, and Deferasirox) was influenced by hepatic iron levels over a follow up of 18 months. In patients treated with Deferasirox and Deferiprone percentage changes in cardiac R2* over 18 months were associated with final liver iron concentration (LIC) and percentage LIC changes. In no chelation group percentage changes in cardiac R2* were influenced by initial LIC or initial cardiac R2*.

This abstract and the presentation materials are available to members only; a login is required.

Join Here